Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways. It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability). It also acts on appetite/satiety centres, contributing to reduced food intake. Key Benefits Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence). Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials. Cardiometabolic improvements associated with weight loss and incretin pathway activity. Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).